

Title

Biofilm inhibitor tauroolithocholic acid alters colony morphology, specialized metabolism, and virulence of *Pseudomonas aeruginosa*

Short Title

Biofilm inhibition alters colony morphology, specialized metabolism, and virulence of *P. aeruginosa*

Authors

Alanna R. Condren¹, Lisa Juliane Kahl², George Kritikos³, Manuel Banzhaf³, Lars E. P. Dietrich², and Laura M. Sanchez^{1*}

Affiliations

1. Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL 60612
2. Department of Biological Sciences, Columbia University, New York, NY 10027
3. Institute of Microbiology & Infection and School of Biosciences, University of Birmingham, Edgbaston, Birmingham, UK.

Author Contributions

Wrote the paper: ARC, LK, GK, MB, LD, LMS

Conceptualized the research: ARC, LMS

Conducted the experiments: ARC, LK, MB, GK

Provided strains: LK, LD

Supervised the research: MB, LD, LMS

Correspondence

sanchelm@uic.edu

Abstract

Biofilm inhibition by exogenous molecules has been an attractive strategy for the development of novel therapeutics. We investigated the biofilm inhibitor tauroolithocholic acid (TLCA) and its effects on the specialized metabolism, virulence and biofilm formation of the clinically relevant bacterium *Pseudomonas aeruginosa* strain PA14. Our study shows that TLCA alters specialized

metabolism, thereby affecting *P. aeruginosa* colony biofilm physiology. We observed an upregulation of metabolites correlated to virulence such as the siderophore pyochelin. A wax moth virulence assay confirmed that treatment with TLCA increases virulence of *P. aeruginosa*. Based on our results, we believe that future endeavors to identify biofilm inhibitors must consider how a putative lead is altering the specialized metabolism of a bacterial community to prevent pathogens from entering a highly virulent state.

Introduction

The ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) have been deemed a severe threat, as the major cause of nosocomial infections, by evolving mechanisms to “escape” the biocidal action of antibiotics [1,2]. The Center for Disease Control and Prevention estimates that costs related to nosocomial infections, which have increased in frequency in all countries regardless of income or industrial development, are between \$680 to \$5,683 USD on average per patient [3].

P. aeruginosa, one of the ESKAPE microorganisms, is often referred as a “ubiquitous” bacterium because of its ability to adapt to a wide variety of environments and hosts [4]. *P. aeruginosa* can be found in the lung cavity of cystic fibrosis patients, colonizing large open wounds of burn victims in hospitals, or invading the cornea of the human eye leading to permanent vision loss [5–7]. *P. aeruginosa* infections are often complicated by the fact that it readily forms a multicellular aggregate known as a biofilm - a state which contributes towards its resistance to antibiotics [8]. The minimum bactericidal concentration for cells in a biofilm state is estimated to be 10-1000 times higher than their planktonic counterparts complicating treatment of biofilm infections [9]. *P. aeruginosa* tightly regulates biofilm formation using molecular signaling networks and a well-characterized arsenal of specialized metabolites [10–14]. Specialized metabolites encompass the bioactive small molecules produced by a given

organism outside of those needed for primary metabolism [15]. Yet, there are currently no biofilm inhibitors on the market in the US [16].

There are, however, several biofilm inhibitors used for *in vitro* analysis of biofilm dispersal [17]. One example is tauro lithocholic acid (TLCA), a bile acid which efficiently inhibits biofilm formation and induces dispersion of mature *P. aeruginosa* biofilms [18,19]. TLCA demonstrated a low micromolar biofilm inhibitory concentration (BIC_{50}) against *P. aeruginosa* at 38.4 μ M compared to other lithocholic and bile acid derivatives [18]. Bile acids are a class of acidic steroids that play a physiological role in digestion by solubilizing dietary fats [20]. Though bile acids are classified as detergents, the steroid control cholesterol 3-sulfate, does not inhibit biofilm formation nor do other bile acids tested at concentrations up to 1 mM. However, all lithocholic bile acids have specific bioactivity against *P. aeruginosa* which varies based on the conjugation to glycine or taurine [18]. Additionally, the reported BIC_{50} of TLCA was in the low micromolar range while the maximum critical micelle concentration for these bile acids ranges from 8 to 12 mM [20]. Therefore, we hypothesized that when TLCA enters the microorganism's chemical space, it induces *P. aeruginosa* to alter the production of specific specialized metabolites leading to the reported biofilm inhibition/dispersion.

We observed altered morphology of colony biofilms and changes in specialized metabolism when *P. aeruginosa* PA14 is exposed to TLCA. An increase in pyochelin production when TLCA is present lead us to perform a wax moth virulence model which confirmed that TLCA treated cells are significantly more virulent than non-treated cells [21]. The observed increase in virulence lead to an investigation into how TLCA may be inducing an increase in pyochelin production to increase virulence. We performed an iron starvation tolerance assay as well as mutant studies via imaging mass spectrometry (IMS) which concluded that TLCA treatment does not make *P. aeruginosa* cells sensitive to iron starvation and a knockout of the *pqsH* ($\Delta pqsH$) and *phzA1-G1 phzA2-G2* (Δphz) gene clusters also leads to an increase in

pyochelin production as observed for the wild-type strain [22]. Taken together, while TLCA has shown promising bioactivity towards biofilm inhibition, it appears that biofilm inhibition (or dispersion) ultimately leads to the bacterium becoming more virulent in a host model, which is supported by the observed alteration in specialized metabolism.

Methods & Materials

TLCA stock solution preparation. Taurolithocholic acid was purchased from Sigma Aldrich ($\geq 98\%$). A 0.5 M stock solution was made by dissolving TLCA in methanol. This solution was then sterile filtered with a 0.22 μm sterile filter and stored at -80°C .

Colony Morphology Studies. Liquid agar was prepared by autoclaving 1% tryptone (Teknova), 1% agar (Teknova) mixture. The liquid agar was cooled to 60°C and Congo Red (EMD; final concentration 40 $\mu\text{g/mL}$) and Coomassie Blue (EMD; final concentration: 20 $\mu\text{g/mL}$) were added. TLCA stock solution, dissolved in MeOH, was vortexed for 2-3 minutes until clear. TLCA was added to liquid agar, different amounts were added to reach the final concentrations of 100 μM , 250 μM , and 1 mM TLCA. Sixty mL of liquid agar mixture was poured into square plates (LDP, 10 cm x 10 cm x 1.5 cm) and left to solidify for ~18-24 hours. Precultures of *P. aeruginosa* PA14 were grown in LB for 12-16 h at 37°C while shaking at 250 rpm. Subcultures were prepared as 1:100 dilutions of precultures into fresh LB media and shaking for 2.5 hours at 37°C , at which point all subcultures had reached mid-exponential phase (optical density of ~0.4-0.6 at 500 nm). Morphology plates were dried for 20-30 min and 10 μL spots of subculture were spotted onto a morphology plate, with not more than four colonies per plate. Colony biofilms were grown at 25°C and high humidity ($+90\%$) for up to 5 days. Images were taken every 24 hours with a Keyence VHX-1000 microscope.

Imaging mass spectrometry experiments. TLCA and the respective vehicle were imbedded into liquid agar prior to plating. LB agar was autoclaved and cooled to 55°C before adding TLCA. A

calculated aliquot of sterilized TLCA stock solution was added to achieve the desired concentration of 250 μ M. Plates were stored in 4 \square refrigerator until needed. *P. aeruginosa* PA14 was plated on Bacto LB agar and grown overnight at 30 \square . A colony from the plate was then used to inoculate a 5 mL LB liquid culture of *P. aeruginosa* and grown overnight at 30 \square shaking at 225 rpm. Overnight liquid cultures (5 μ L) was spotted on thin agar plates (10 mL of agar in 90 mm plate) embedded with either TLCA or the vehicle (MeOH) and incubated for 48 hours at 30 \square . Humidity/moisture was removed from environment during growth by placing a small amount of Drierite in the incubator. Following 48 hours of growth, colonies were excised from agar plates using a razor blade and transferred to an MSP 96 target ground steel target plate (Bruker Daltonics). An optical image of the colonies on the target plate was taken prior to matrix application. A 53 μ m stainless steel sieve (Hogentogler Inc) was used to coat the steel target plate and colonies with MALDI matrix. The MALDI matrix used for the analysis was a 1:1 mixture of recrystallized α -cyano-4-hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB) (Sigma). The plate was then placed in an oven at 37 \square for approximately four hours or until the agar was fully desiccated. After four hours, excess matrix was removed from target plate and sample with a stream of air. Another optical image was taken of the desiccated colonies on the target plate. The target plate and desiccated colony were then introduced into the MALDI-TOF mass spectrometer (Bruker Autoflex Speed) and analyzed with FlexControl v.3.4 and FlexImaging v.4.1 software. The detector gain and laser power must be optimized for each imaging run to achieve acceptable signal to noise, as an example, in figure 2, the detector gain and laser power were set at 3.0x and 41% respectively. Range of detection was from 100 Da to 3,500 Da with ion suppression set at 50 Da in positive reflectron mode. The raster size was set to 500 μ m and the laser was set to 200 shots per raster point at medium (3) laser size.

Statistical analysis of Imaging Data. SCiLS software (Bruker, version 2015b) was used to run statistical analysis of raw imaging data. Settings for analysis was as follows: Normalization: root

mean square (RMS), error: ± 0.2 Da, and weak denoising for segmentation. Using “Find Discriminative Values (ROC)” for unbiased analysis, PA14 control colony was selected as class 1 and TLCA treated colony as class 2 and SCiLS identified signals that were significantly upregulated in class 1 (MeOH control colony) with a threshold of 0.75 corresponding to a Pearson correlation of $p < 0.05$. In our report, these signals are referred to as “downregulated” since they have a higher intensity in the control. The same analysis was performed with the classes flipped to identify signals that were upregulated in TLCA condition. Statistical analysis was completed after calculating mass error (**Table S2**) of three biological replicates (N=3) (**Figures S3-S5**) and signals were only considered significant if altered regulation was observed in two or more replicates.

Iron Stress Tolerance Assay: The protocol for the iron stress tolerance assay used was exactly as described by Chua *et al.* [22], with the exceptions that strain PA14 rather than PAO1 and a 1 mM of TLCA and 2’2-bipyridine (DIPY) were used. The OD at 600 nm of each liquid culture was measured every 15 minutes for 16 hours.

Galleria mellonella treatment assays. *Galleria mellonella* larvae (greater wax moth) were purchased from TrueLarv UK Ltd. (Exeter, UK) and stored at 15°C prior to use. The assay was performed as described previously [23], except for the following differences: PA14 wild-type (WT) cells were grown exponentially for 2 hours, washed with PBS buffer and adjusted to an OD₍₆₀₀₎ of 0.1. The PA14 culture was further diluted with PBS and plated to determine the CFU of the inoculation suspension. Larvae were inoculated with 20 μ L of a 2.5×10^3 CFU/mL solution and incubated at 37°C for 2 hours. After this incubation time, larvae were injected with 20 μ L of compound or PBS. The final concentration of TLCA and sodium nitroprusside (SNP) was 250 μ M. For controls, uninfected larvae were administered the same compound dose to monitor for toxicity. In parallel one group of larvae received two sterile 20 μ L PBS injections to control for unintentional killing by the injections. In total 25 larvae were used per condition, split

in two independent experiments. In total 10 larvae were used for the PBS only condition. Survival of a larvae was determined by the ability to respond to external stimuli (poking). Larvae survival was estimated using the Kaplan-Meier estimator.[24] Survival estimates were subsequently compared using the log-rank test [25]. Resulting p-values were corrected using the Benjamini-Hochberg method [26] (**Figure S3**).

pqs mutants IMS analysis. Mutants proceeded through the same protocol as the WT (PA14) bacterial colonies (**Table S10**). IMS sample prep and experimentation was completed at the same settings as described in “Imaging mass spectrometry experiments” section. Statistical analysis was completed after calculating mass error (**Table S4-S8**) of three biological replicates (N=3) and signals were only considered significant if altered regulation was observed in two or more replicates.

PQS complementation. The complementation strains *P. aeruginosa* PA14 $\Delta pqsA-C::pqsA-C$, $\Delta pqsH::pqsH$, and $\Delta pqsL::pqsL$ were constructed as described in Jo *et al.* [57]. Primers LD1 & LD4, LD168 & LD171, and LD9 & LD12 were used to amplify the *pqsA-C*, *pqsH* and *pqsL* genes, respectively (**Table S10**). Correct constructs were confirmed by PCR and sequencing and complemented into the original deletion site, following the same procedure as for deletion.

Bacterial Extraction for PCA and PCH Fold-change. Bacterial growth for quantification proceeded exactly as described in “Imaging mass spectrometry experiments”. Each strains (PA14 WT, $\Delta pqsA-C$, $\Delta pqsH$, Δphz , $\Delta pqsA-C::pqsA-C$, and $\Delta pqsH::pqsH$) was plated in duplicate. After 48 hours, a spatula was used to separate the entire colony and surrounding agar from petri dish. Samples were transferred to a glass vial. Each vial was filled with 2-3 mL of DI water and homogenized using a spatula. Vials were either flash frozen or stored at -80°C prior to lyophilization. Upon dryness, 3mL of MeOH was added to each vial and samples were

sonicated for 30 minutes to extract organics. Total weights of each sample dry biomass were used to achieve a 10mg/mL solution of each extract. 10mg/mL solutions were centrifuged at 10,000 rpm for 2 minutes before transferring to HPLC vials for analysis. (Repeated for a total of two biological replicates).

PCA and PCH Fold-change analysis. PCA standard was purchased from ChemScience (>97%). An HPLC method previously described by *Adler et al.* was used on an Agilent 1260 Infinity to isolate and identify PCA through retention time matching with standard (32.5 min at 250 nm; **Figure S7**) with a Phenomenex C18 analytical column (150 x 4.6 mm; 5 μ m) and a flow rate of 0.5 mL/min [27]. Area under the curve (AUC) was used to quantify fold-change between PA14 WT and other strains/conditions. For PCH fold-change quantification, a gradient of 10%-85% ACN (0.1% TFA) and H2O (0.1% TFA) over 25 minutes with the two PCH stereoisomers (pyochelin I and II) eluting at 16.0 & 16.2 minutes respectively at 210 nm. Area reported for fold change analysis was achieved by combining the AUC of the peaks for pyochelin I and II. Fold-change analysis was determined averaging the areas of EICs for two independent biological cultures (N=2), with three technical replicates (n=3), and compared to PA14 WT with no TLCA (control).

Results & Discussion

Phenazines constitute one of the most notable families of specialized metabolites produced by *P. aeruginosa*. Phenazines are redox-active compounds that have been implicated in balancing redox homeostasis in the hypoxic regions of biofilms, thereby regulating biofilm morphology [28–32]. A phenazine-null mutant (Δphz) over produces extracellular matrix which causes Δphz biofilms to have a characteristic hyper wrinkled morphology that allows for increased access to oxygen due to a higher surface area-to-volume ratio [32–35]. To characterize the effect of TLCA on *P. aeruginosa* biofilms, we grew PA14 colonies in a colony morphology assay on solid agar supplemented with Congo Red, Coomassie Blue, and TLCA (0,

100, 250, and 1000 μ M) for five days (**Figure S1**). Wild type PA14 initially forms a smooth colony but initiates wrinkle structure development after 70 hours (**Figure 1**). In contrast, a Δphz mutant showed enhanced production of biofilm matrix, leading to an earlier onset of wrinkling between 24 and 48 hours. Addition of TLCA to the medium promoted a hyper-wrinkled morphology after 94 hours. The colony continued to wrinkle over time, resembling the Δphz mutant (118 hours; **Figure 1**). This morphology phenotype was also observed at lower concentrations, but it was most dramatic at 1 mM TLCA, which is a physiologically relevant concentration [36] (**Figure S1**). Based on this assay, it appears that TLCA induces matrix production, possibly by downregulating phenazines.

The putative decrease in phenazine production as indicated by the Δphz -like colony morphology in the presence of TLCA was queried alongside other changes in specialized metabolism using imaging mass spectrometry (IMS). We employed matrix-assisted laser desorption/ionization time-of-flight IMS (MALDI-TOF IMS), because it provides a robust, untargeted analysis of the specialized metabolites produced by *P. aeruginosa in situ* [37,38]. *P. aeruginosa* colonies were grown on thin agar (2-3 mm) embedded with the vehicle or 250 μ M of TLCA for 48 hours. The colonies and their respective agar controls were then prepared for IMS analysis. Twelve known specialized metabolites were identified and visualized from *P. aeruginosa* colonies (**Figure 2**). Orthogonal analytical techniques were used to confirm identities of all twelve metabolites (**Figure S2**). Following a combination of manual and statistical analyses using SCiLS lab, eight of the twelve specialized metabolites were observed to have significant altered regulation in the presence of TLCA ($p < 0.05$; **Table S1**). The identified specialized metabolites represent four broad classes of molecular families including the phenazines, quinolones, rhamnolipids, and siderophores. We found that the phenazines pyocyanin (PYO) and phenazine-1-carboxamide (PCN) are significantly downregulated when TLCA is present, supporting our hypothesis that TLCA exposure causes hyper-wrinkled colonies

by downregulating phenazine production. We did not observe a statistically significant change in phenazine-1-carboxylic acid (PCA) production in the presence of TLCA. Since methylated phenazines like PYO, but not PCN and PCA were shown to inhibit colony wrinkling [39] our data is consistent with TLCA affecting colony morphology by modulating phenazine production.

P. aeruginosa is reported to produce up to 50 quinolones which are specialized metabolites that play specific roles in signaling and/or virulence. For example, both 2-heptyl-4-quinolone (HHQ) and *Pseudomonas* quinolone signal (PQS) are specifically known for their signaling properties but have also demonstrated antifungal bioactivity [40–46]. The N-oxide quinolone, 4-hydroxy-2-heptylquinoline-N-oxide (HQNO), has recently been shown to have antimicrobial activity towards Gram-positive bacteria and contributes to *P. aeruginosa*'s virulence [40–45]. When exposed to TLCA, we observed a significant upregulation of HHQ, PQS, and 4-hydroxy-2-nonylquinoline (HNQ) within the colony. PQS is a well-characterized signaling molecule in *P. aeruginosa* quorum sensing cascade [47]. Though IMS is a valuable tool for identifying and visualizing the chemical composition of a sample, it cannot differentiate between constitutional isomers like HQNO and PQS (m/z 260; **Figure 2**). In order to differentiate these two metabolites, we used a combination of tandem mass spectrometry and knockout mutants to demonstrate that PQS was represented by the signal that is retained in the colony (center, upregulated) and HQNO corresponds to the signal that was excreted into the agar (outer signal, downregulated) (**Figure S3**). HHQ and PQS are well established signaling molecules that are required for phenazine production in *Pseudomonas aeruginosa*. However, since we observed decreased phenazine levels despite an increase in quinolone production [48] our results suggest that TLCA is attenuating phenazine production in a quinolone-independent manner.

Based on the IMS analyses, treatment of TLCA seems to induce the production of biosurfactants. These compounds, such as rhamnolipids, are amphipathic small molecules that

P. aeruginosa produces to increase surface adhesion and motility [49]. Rha-Rha-C10-C10 and Rha-Rha-C12-C10/C10-C12 production were produced at elevated levels after treatment with TLCA (**Figure 2**). However, while these results were not statistically significant, the trend is worth noting because increases in rhamnolipid production would agree with the previously reported bioactivity of TLCA. In colony biofilms, TLCA markedly increases matrix production and leads to increased spreading and wrinkling. This wrinkly spreader phenotype is reminiscent of the phenazine-null mutant as seen in **Figure 1**.

In addition to quinolones and phenazines, we detected changes in the levels of the siderophore pyochelin. Siderophores are iron chelators that allow bacteria to acquire iron from the surrounding environment [50]. Siderophores have been known to sequester iron from host proteins and simultaneously act as signals for biofilm development [12]. The IMS results show a significant upregulation of pyochelin in the presence of TLCA (**Figure 2**). Pyochelin is produced by the biosynthetic pathway *pchA-I* which is activated by the presence of both iron and the ferric uptake regulator (Fur) [12]. Additionally, previous work has shown that an increase in iron-bound PQS can indirectly increase siderophore production by activating the siderophore gene clusters *pvd* and *pch*. Our IMS experiments on wild-type PA14 (**Figure 2**) confirm this relationship due to the increase of both PQS and pyochelin in the presence of TLCA. Siderophores have antimicrobial activity and contribute to virulence [51,52]. Hence, the TLCA-dependent upregulation of pyochelin raised the question of whether TLCA-exposed *P. aeruginosa* become hypervirulent.

Many bacteria, like the ESKAPE pathogens, exhibit distinct lifestyle states depending on surrounding environmental factors. Chua *et al.* recently described characteristics of the dispersed cell state using sodium nitroprusside (SNP) as a biofilm-dispersing agent [22]. They found that dispersed cells are characterized by altered physiology, increased virulence against macrophages and *C. elegans*, and extreme sensitivity to iron starvation [22]. Having observed an increase in pyochelin production when exposing *P. aeruginosa* to TLCA (**Figure 2**), we

sought to determine if TLCA treated cells were hypervirulent using a *Galleria mellonella* (greater wax moth) larvae virulence assay.

G. mellonella larvae have been shown to be an ideal model for studying microbial pathogenesis of several ESKAPE pathogens since they are easily infected, inexpensive, and produce a similar immune response as vertebrates and mammals [53–57]. Larvae were injected with a *P. aeruginosa* or vehicle load, and exposed to SNP, TLCA, or no dispersing agent two hours post infection. In the infected TLCA-exposed larvae, a 50% decrease in survival rate was observed 17 hours post infection compared to the infected larvae that did not receive a dispersing agent (**Figure 3**). In the *G. mellonella* model, the potency of treatment is gauged by the survival curve, therefore a shift in this curve will indicate increased or decreased virulence of *P. aeruginosa* as compared to the 50% survival rate of non-treated infected larvae [58].

Addition of SNP or TLCA lead to a significant decrease in survival with 50% of the larvae succumbing to infection 1-2 hours earlier than the PA14 control. Exposure to either of the biofilm inhibitors, SNP or TLCA, did not affect the survival rate of uninfected larvae. TLCA-dispersed cells are also hypervirulent and have an analogous trend to SNP-dispersed cells. This confirms that TLCA-dispersed cells are significantly more virulent than planktonic or biofilm cells as previously observed with SNP-dispersed cells (**Table S3**; $p < 0.05$).

Having confirmed that TLCA increases virulence in *P. aeruginosa*, we were interested in testing whether *P. aeruginosa* TLCA-treated cells would also be sensitive to iron stress and whether this may be related to the increase in pyochelin production. In SNP-dispersed cells, pyoverdine the other main siderophore produced by *P. aeruginosa*, was markedly decreased and these dispersed cells showed a sensitivity to iron starvation [22]. However, we were unable to detect pyoverdine in either the wild type or TLCA-treated *P. aeruginosa* via mass spectrometry, but were able to detect pyochelin which Chua *et al.* did not measure (Figure 2). Therefore, we recapitulated the iron starvation assay performed by Chua *et al.* to determine if TLCA exposure induces sensitivity to iron starvation as shown for SNP-dispersed cells.

Iron starvation was induced by exposing PA14 cells to the iron chelator 2'2-bipyridine (DIPY; **Figure 4**). This assay was performed with TLCA-dispersed biofilm cells, which were generated from pellicles (biofilms grown at the air-liquid interface) (**Figure 4A & B**), and planktonic cells, where exposure to TLCA acted to inhibit biofilm formation (**Figure 4C & D**). Proliferation of the cells was monitored by measuring optical density at 600 nm of each condition over 16 hours. TLCA exposure alone does not alter proliferation compared to the untreated control (**Figure 4B**). While exposure to DIPY, which induces iron starvation, significantly decreases proliferation ($p < 0.05$) of biofilm-derived cells during the log phase of growth (120-540 mins) (**Figure 4B**). However, there is no significant difference between biofilm cells and TLCA-dispersed biofilm cells when exposed to iron starvation. We observe the same trends when inhibiting biofilm formation of planktonic cells with TLCA (**Figure 4D**). Therefore, unlike for SNP, TLCA-dispersed cells are not sensitive to iron starvation.

The discrepancy in iron starvation sensitivity might be attributed to their different effects on pyoverdine production. Though we were unable to detect pyoverdine in our IMS analysis, iron starvation might be prevented by the increased presence of pyochelin in colony biofilms that were exposed to TLCA (Figure 2). Despite their differing effects on iron starvation sensitivity, both SNP and TLCA have previously been shown to readily disperse biofilms, likely through different mechanisms of action [18,22]. SNP, a nitric oxide donor, has been shown to disperse mature biofilms by producing nitrosative stress inside of the biofilm structure [21]. Since TLCA cannot act as a nitric oxide donor and it does not cause cell lysis, TLCA must act via an alternative mechanism to disperse biofilms [18]. This, along with results, supports our hypothesis that TLCA exposure induces alterations to *P. aeruginosa*'s specialized metabolism.

PQS is a major quorum sensing signal and iron-bound PQS upregulates siderophore production [59]. The increase in pyochelin production *in situ* and the enhanced virulence *in vivo* lead us to investigate the contribution of the *pqs* gene cluster to the TLCA-mediated effect. We tested four mutants with deletions in quinolone and phenazine biosynthetic genes: $\Delta pqsA-C$,

ΔpqsH, *ΔpqsL*, and *Δphz*. *ΔpqsA-C* does not produce any quinolones, while *ΔpqsH* cannot produce PQS and *ΔpqsL* cannot produce N-oxide quinolones such as HQNO [48,60,61]. The phenazine-null mutant, *Δphz*, is a double-deletion of the two redundant core phenazine biosynthetic gene clusters *phzA1-G1* and *phzA2-G2* [48,60,61]. Using IMS, we investigated if any of the four mutants would recapitulate the TLCA-dependent increase in pyochelin production that we observed for the WT. No variation in pyochelin production for *ΔpqsA-C* and *ΔpqsL* mutants were found, while *ΔpqsH* mutant produced significantly more pyochelin in response to TLCA, mimicking the trend observed in the WT ($p < 0.05$; **Figure S6**). This result puts into question our earlier assumption that PQS and pyochelin production are positively correlated. We also observed a significant increase in pyochelin production in the *Δphz* mutant (**Figure S6**). Previous work has shown that increasing PCA concentrations allows PA14 siderophore-null mutants to still develop biofilms and sequester iron [62]. This may be due to phenazine's ability to mediate the reduction of Fe(III) to the bioavailable Fe(II) [62]. *pqsH* and *phz* gene clusters are necessary for phenazine production, hence a decrease or lack of phenazine production due to TLCA exposure might lead to the observed increase in pyochelin production (**Figures 2 & S6**).

Since our IMS results were inconclusive regarding the effect of TLCA on PCA production in colony biofilms (**Figure 2**), we subjected bacterial colony extracts from wild-type PA14, *ΔpqsH*, and *Δphz* to an HPLC analysis to measure fold change across biological (N=3) and technical replicates (n=3) (**Figure 5A**). When considering fold changes greater than ± 1 , PCA production was not altered by TLCA exposure in the wild type and *ΔpqsH* strains (not produced by *Δphz* mutant). However, an increase in pyochelin production was observed in the TLCA-exposed *Δphz* mutant (+2.20) (**Figure 5B**). When the *ΔpqsH* mutant is complemented (*ΔpqsH::pqsH*) there is increased production of pyochelin compared to wild-type whether the colony is TLCA-treated or not (+2.43 and +1.81, respectively) (**Table S9**). There was no notable

difference in production of pyochelin in the complementation strain whether it was TLCA-treated or not, which recapitulates the wild-type data. Though the fold change of PCA and pyochelin was comparable in both wild-type PA14 and $\Delta pqsH$, the change in the production of these two metabolites in the phenazine-null mutant, Δphz , suggests that a lack of phenazine production is correlated to the observed increase in pyochelin production from cells exposed to TLCA.

Conclusion

In this study we demonstrate that the endogenous enteric biofilm inhibitor, TLCA, can alter colony morphology, specialized metabolism, and virulence of *P. aeruginosa*. Our biological and chemical studies confirm what is already known about TLCA's bioactivity and offers insight into the chemical communication occurring between the cells upon treatment with a known biofilm inhibitor. TLCA-dispersed biofilm cells are not sensitive to iron starvation, as previously reported for the biofilm-dispersing agent SNP, however dispersion via either agent induces a significant increase in virulence *in vivo*, implying that the mechanism of action of the two biofilm inhibitors is different. Our IMS analysis of mutant strains revealed that when exposed to TLCA, a lack of PQS ($\Delta pqsH$) or phenazine production (Δphz) lead to an increase in pyochelin production, matching the results observed in our colony morphology and IMS WT experiments. Therefore, PQS or iron-bound PQS is not responsible for activating the *pchA-I* gene cluster (**Figure 6A**). However, IMS analysis highlighted that a significant increase in pyochelin production was observed in the Δphz mutant confirming that the *phz* gene cluster plays a role in increased pyochelin production when TLCA is present (**Figure 6B**). Though these results are not conclusive regarding the mechanism of TLCA dispersal since biofilm inhibition and dispersal cannot be tested using colony biofilms as a model system, it does support the hypothesis that TLCA is acting as an environmental cue to induce *P. aeruginosa* to alter its metabolic signaling throughout the bacterial community, thus disrupting the biofilm life cycle.

More work is needed to determine the mechanism of action of TLCA, but our work shows that through TLCA exposure *P. aeruginosa* bacterial communities increase the

production of virulence factors such as pyochelin and consequently develop hypervirulence *in vivo*. Others have documented similar phenomena by reporting an increase in virulence *in vivo* as a consequence of exposure to a biofilm inhibitor in organisms such as, Group A *Streptococcus*, *Vibrio cholerae*, and *Candida albicans* [63–67]. Taken into consideration previous literature, our work promotes that future investigations must consider how biofilm inhibitors alter the chemical environment within a bacterial biofilm and that biofilm inhibition as a treatment strategy should be closely monitored for variations in specialized metabolism leading to undesired side effects such as increased virulence.

Acknowledgements

We thank Drs. Atul Jain and Terry Moore for assisting with the recrystallization of the MALDI matrices. Funding was provided by Grant K12HD055892 from the National Institute of Child Health and Human Development (NICHD) and the National Institutes of Health Office of Research on Women's Health (ORWH) (L.M.S.); University of Illinois at Chicago Startup Funds (L.M.S.); American Society for Pharmacognosy research startup grant (L.M.S.); NIH/NIAID grant R01AI103369 and an NSF CAREER award (L.E.P.D). ARC was supported in part by the National Science Foundation Illinois Louis Stokes Alliance for Minority Participation Bridge to the Doctorate Fellowship (grant number 1500368) and a UIC Abraham Lincoln retention fellowship.

References

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J Infect Dis.* 2008;197: 1079–1081.
2. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. *Infect Control Hosp Epidemiol.* 2010;31 Suppl 1: S7–10.
3. Kouchak F, Askarian M. Nosocomial infections: the definition criteria. *Iran J Med Sci.* 2012;37: 72–73.
4. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect Dis.* 2006;6: 130.
5. Spencer WH. *Pseudomonas aeruginosa* infections of the eye. *Calif Med.* 1953;79: 438–443.
6. Norbury W, Herndon DN, Tanksley J, Jeschke MG, Finnerty CC. Infection in Burns. *Surg*

- 413 Infect . 2016;17: 250–255.
- 414 7. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A Comprehensive Analysis
415 of the Impact of *Pseudomonas aeruginosa* Colonization on Prognosis in Adult
416 Bronchiectasis. *Ann Am Thorac Soc*. 2015;12: 1602–1611.
- 417 8. Hall CW, Hinz AJ, Gagnon LB-P, Zhang L, Nadeau J-P, Copeland S, et al. *Pseudomonas*
418 *aeruginosa* Biofilm Antibiotic Resistance Gene *ndvB* Expression Requires the RpoS
419 Stationary-Phase Sigma Factor. *Appl Environ Microbiol*. 2018;84. doi:10.1128/AEM.02762-
420 17
- 421 9. Wu H, Moser C, Wang H-Z, Høiby N, Song Z-J. Strategies for combating bacterial biofilm
422 infections. *Int J Oral Sci*. 2015;7: 1–7.
- 423 10. Mukherjee S, Moustafa DA, Stergioula V, Smith CD, Goldberg JB, Bassler BL. The PqsE
424 and RhlR proteins are an autoinducer synthase-receptor pair that control virulence and
425 biofilm development in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A*. 2018;115:
426 E9411–E9418.
- 427 11. Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Cámara M. Quinolones: from
428 antibiotics to autoinducers. *FEMS Microbiol Rev*. 2011;35: 247–274.
- 429 12. Banin E, Vasil ML, Greenberg EP. Iron and *Pseudomonas aeruginosa* biofilm formation.
430 *Proc Natl Acad Sci U S A*. 2005;102: 11076–11081.
- 431 13. Cezairliyan B, Vinayavekhin N, Grenfell-Lee D, Yuen GJ, Saghatelian A, Ausubel FM.
432 Identification of *Pseudomonas aeruginosa* phenazines that kill *Caenorhabditis elegans*.
433 *PLoS Pathog*. 2013;9: e1003101.
- 434 14. Das T, Kutty SK, Tavallaie R, Ibugo AI, Panchompoo J, Sehar S, et al. Phenazine virulence
435 factor binding to extracellular DNA is important for *Pseudomonas aeruginosa* biofilm
436 formation. *Sci Rep*. 2015;5: 8398.
- 437 15. Davies J. Specialized microbial metabolites: functions and origins. *J Antibiot* . 2013;66:
438 361–364.
- 439 16. Stewart PS. Prospects for Anti-Biofilm Pharmaceuticals. *Pharmaceuticals* . 2015;8: 504–
440 511.
- 441 17. Rabin N, Zheng Y, Opoku-Temeng C, Du Y, Bonsu E, Sintim HO. Agents that inhibit
442 bacterial biofilm formation. *Future Med Chem*. 2015;7: 647–671.
- 443 18. Sanchez LM, Cheng AT, Warner CJA, Townsley L, Peach KC, Navarro G, et al. Biofilm
444 Formation and Detachment in Gram-Negative Pathogens Is Modulated by Select Bile
445 Acids. *PLoS One*. 2016;11: e0149603.
- 446 19. Sanchez LM, Wong WR, Riener RM, Schulze CJ, Linington RG. Examining the fish
447 microbiome: vertebrate-derived bacteria as an environmental niche for the discovery of
448 unique marine natural products. *PLoS One*. 2012;7: e35398.
- 449 20. Monte MJ, Marin JJG, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and
450 pathophysiology. *World J Gastroenterol*. 2009;15: 804–816.

- 451 21. Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS. Involvement of nitric
452 oxide in biofilm dispersal of *Pseudomonas aeruginosa*. *J Bacteriol.* 2006;188: 7344–7353.
- 453 22. Chua SL, Liu Y, Yam JKH, Chen Y, Vejborg RM, Tan BGC, et al. Dispersed cells represent
454 a distinct stage in the transition from bacterial biofilm to planktonic lifestyles. *Nat Commun.*
455 2014;5: 4462.
- 456 23. Desbois AP, Coote PJ. Wax moth larva (*Galleria mellonella*): an in vivo model for assessing
457 the efficacy of antistaphylococcal agents. *J Antimicrob Chemother.* 2011;66: 1785–1790.
- 458 24. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *J Am Stat*
459 *Assoc.* Taylor & Francis; 1958;53: 457–481.
- 460 25. Bland JM, Altman DG. The logrank test. *BMJ.* 2004;328: 1073.
- 461 26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
462 Approach to Multiple Testing. *J R Stat Soc Series B Stat Methodol.* 1995;57: 289–300.
- 463 27. Adler C, Corbalán NS, Seyedsayamdost MR, Pomares MF, de Cristóbal RE, Clardy J, et al.
464 Catecholate siderophores protect bacteria from pyochelin toxicity. *PLoS One.* 2012;7:
465 e46754.
- 466 28. Recinos DA, Sekedat MD, Hernandez A, Cohen TS, Sakhtah H, Prince AS, et al.
467 Redundant phenazine operons in *Pseudomonas aeruginosa* exhibit environment-
468 dependent expression and differential roles in pathogenicity. *Proc Natl Acad Sci U S A.*
469 2012;109: 19420–19425.
- 470 29. Price-Whelan A, Dietrich LEP, Newman DK. Pyocyanin alters redox homeostasis and
471 carbon flux through central metabolic pathways in *Pseudomonas aeruginosa* PA14. *J*
472 *Bacteriol.* 2007;189: 6372–6381.
- 473 30. Price-Whelan A, Dietrich LEP, Newman DK. Rethinking “secondary” metabolism:
474 physiological roles for phenazine antibiotics. *Nat Chem Biol.* 2006;2: 71–78.
- 475 31. Mentel M, Ahuja EG, Mavrodi DV, Breinbauer R, Thomashow LS, Blankenfeldt W. Of two
476 make one: the biosynthesis of phenazines. *Chembiochem.* 2009;10: 2295–2304.
- 477 32. Okegbe C, Fields BL, Cole SJ, Beierschmitt C, Morgan CJ, Price-Whelan A, et al. Electron-
478 shuttling antibiotics structure bacterial communities by modulating cellular levels of c-di-
479 GMP. *Proc Natl Acad Sci U S A.* 2017;114: E5236–E5245.
- 480 33. Briard B, Bomme P, Lechner BE, Mislin GLA, Lair V, Prévost M-C, et al. *Pseudomonas*
481 *aeruginosa* manipulates redox and iron homeostasis of its microbiota partner *Aspergillus*
482 *fumigatus* via phenazines. *Sci Rep.* 2015;5: 8220.
- 483 34. Wang Y, Newman DK. Redox reactions of phenazine antibiotics with ferric (hydr)oxides and
484 molecular oxygen. *Environ Sci Technol.* 2008;42: 2380–2386.
- 485 35. Ramos I, Dietrich LEP, Price-Whelan A, Newman DK. Phenazines affect biofilm formation
486 by *Pseudomonas aeruginosa* in similar ways at various scales. *Res Microbiol.* 2010;161:
487 187–191.
- 488 36. Hofmann AF, Eckmann L. How bile acids confer gut mucosal protection against bacteria.

- 489 Proc Natl Acad Sci U S A. 2006;103: 4333–4334.
- 490 37. Cleary JL, Condren AR, Zink KE, Sanchez LM. Calling all hosts: Bacterial communication in
491 situ. Chem. 2017;2: 334–358.
- 492 38. Galey MM, Sanchez LM. Spatial Analyses of Specialized Metabolites: The Key to Studying
493 Function in Hosts. mSystems. 2018;3. doi:10.1128/mSystems.00148-17
- 494 39. Sakhtah H, Koyama L, Zhang Y, Morales DK, Fields BL, Price-Whelan A, et al. The
495 *Pseudomonas aeruginosa* efflux pump MexGHI-OpnD transports a natural phenazine that
496 controls gene expression and biofilm development. Proc Natl Acad Sci U S A. 2016;113:
497 E3538–47.
- 498 40. Filkins LM, Graber JA, Olson DG, Dolben EL, Lynd LR, Bhuju S, et al. Coculture of
499 *Staphylococcus aureus* with *Pseudomonas aeruginosa* Drives *S. aureus* towards
500 Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model. J Bacteriol.
501 2015;197: 2252–2264.
- 502 41. Phelan VV, Moree WJ, Aguilar J, Cornett DS, Koumoutsis A, Noble SM, et al. Impact of a
503 transposon insertion in *phzF2* on the specialized metabolite production and interkingdom
504 interactions of *Pseudomonas aeruginosa*. J Bacteriol. 2014;196: 1683–1693.
- 505 42. Machan ZA, Taylor GW, Pitt TL, Cole PJ, Wilson R. 2-Heptyl-4-hydroxyquinoline N-oxide,
506 an antistaphylococcal agent produced by *Pseudomonas aeruginosa*. J Antimicrob
507 Chemother. 1992;30: 615–623.
- 508 43. Hoffman LR, Déziel E, D’Argenio DA, Lépine F, Emerson J, McNamara S, et al. Selection
509 for *Staphylococcus aureus* small-colony variants due to growth in the presence of
510 *Pseudomonas aeruginosa*. Proc Natl Acad Sci U S A. 2006;103: 19890–19895.
- 511 44. Biswas L, Biswas R, Schlag M, Bertram R, Götz F. Small-colony variant selection as a
512 survival strategy for *Staphylococcus aureus* in the presence of *Pseudomonas aeruginosa*.
513 Appl Environ Microbiol. 2009;75: 6910–6912.
- 514 45. Voggu L, Schlag S, Biswas R, Rosenstein R, Rausch C, Götz F. Microevolution of
515 cytochrome bd oxidase in *Staphylococci* and its implication in resistance to respiratory
516 toxins released by *Pseudomonas*. J Bacteriol. 2006;188: 8079–8086.
- 517 46. Kim K, Kim YU, Koh BH, Hwang SS, Kim S-H, Lépine F, et al. HHQ and PQS, two
518 *Pseudomonas aeruginosa* quorum-sensing molecules, down-regulate the innate immune
519 responses through the nuclear factor-kappaB pathway. Immunology. 2010;129: 578–588.
- 520 47. Häussler S, Becker T. The *pseudomonas* quinolone signal (PQS) balances life and death in
521 *Pseudomonas aeruginosa* populations. PLoS Pathog. 2008;4: e1000166.
- 522 48. Gallagher LA, McKnight SL, Kuznetsova MS, Pesci EC, Manoil C. Functions required for
523 extracellular quinolone signaling by *Pseudomonas aeruginosa*. J Bacteriol. 2002;184:
524 6472–6480.
- 525 49. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002;8: 881–890.
- 526 50. Cornelis P, Dingemans J. *Pseudomonas aeruginosa* adapts its iron uptake strategies in
527 function of the type of infections. Front Cell Infect Microbiol. 2013;3: 75.

51. Kang D, Kirienko DR, Webster P, Fisher AL, Kirienko NV. Pyoverdine, a siderophore from *Pseudomonas aeruginosa*, translocates into *C. elegans*, removes iron, and activates a distinct host response. *Virulence*. 2018;9: 804–817.
52. Cox CD. Effect of pyochelin on the virulence of *Pseudomonas aeruginosa*. *Infect Immun*. 1982;36: 17–23.
53. Browne N, Heelan M, Kavanagh K. An analysis of the structural and functional similarities of insect hemocytes and mammalian phagocytes. *Virulence*. 2013;4: 597–603.
54. Jander G, Rahme LG, Ausubel FM. Positive correlation between virulence of *Pseudomonas aeruginosa* mutants in mice and insects. *J Bacteriol*. 2000;182: 3843–3845.
55. Insua JL, Llobet E, Moranta D, Pérez-Gutiérrez C, Tomás A, Garmendia J, et al. Modeling *Klebsiella pneumoniae* pathogenesis by infection of the wax moth *Galleria mellonella*. *Infect Immun*. 2013;81: 3552–3565.
56. Jønsson R, Struve C, Jenssen H, Krogfelt KA. The wax moth *Galleria mellonella* as a novel model system to study Enteroaggregative *Escherichia coli* pathogenesis. *Virulence*. 2017;8: 1894–1899.
57. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in *Staphylococcus aureus* infection. *J Infect Dis*. 2009;199: 532–536.
58. Koch G, Nadal-Jimenez P, Cool RH, Quax WJ. Assessing *Pseudomonas* virulence with nonmammalian host: *Galleria mellonella*. *Methods Mol Biol*. 2014;1149: 681–688.
59. Diggle SP, Matthijs S, Wright VJ, Fletcher MP, Chhabra SR, Lamont IL, et al. The *Pseudomonas aeruginosa* 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. *Chem Biol*. 2007;14: 87–96.
60. Lépine F, Milot S, Déziel E, He J, Rahme LG. Electrospray/mass spectrometric identification and analysis of 4-hydroxy-2-alkylquinolines (HAQs) produced by *Pseudomonas aeruginosa*. *J Am Soc Mass Spectrom*. 2004;15: 862–869.
61. Bredenbruch F, Nimtz M, Wray V, Morr M, Müller R, Häussler S. Biosynthetic pathway of *Pseudomonas aeruginosa* 4-hydroxy-2-alkylquinolines. *J Bacteriol*. 2005;187: 3630–3635.
62. Wang Y, Wilks JC, Danhorn T, Ramos I, Croal L, Newman DK. Phenazine-1-carboxylic acid promotes bacterial biofilm development via ferrous iron acquisition. *J Bacteriol*. 2011;193: 3606–3617.
63. Dow JM, Crossman L, Findlay K, He Y-Q, Feng J-X, Tang J-L. Biofilm dispersal in *Xanthomonas campestris* is controlled by cell-cell signaling and is required for full virulence to plants. *Proc Natl Acad Sci U S A*. 2003;100: 10995–11000.
64. Rossmann FS, Racek T, Wobser D, Puchalka J, Rabener EM, Reiger M, et al. Phage-mediated dispersal of biofilm and distribution of bacterial virulence genes is induced by quorum sensing. *PLoS Pathog*. 2015;11: e1004653.
65. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Köhler JR, et al. Dispersion as an important step in the *Candida albicans* biofilm developmental cycle.

- 567 PLoS Pathog. 2010;6: e1000828.
- 568 66. Hay AJ, Zhu J. Host intestinal signal-promoted biofilm dispersal induces *Vibrio cholerae*
569 colonization. *Infect Immun*. 2015;83: 317–323.
- 570 67. Connolly KL, Roberts AL, Holder RC, Reid SD. Dispersal of Group A streptococcal biofilms
571 by the cysteine protease SpeB leads to increased disease severity in a murine model.
572 *PLoS One*. 2011;6: e18984.
- 573 66. Connolly KL, Roberts AL, Holder RC, Reid SD. Dispersal of Group A streptococcal biofilms
574 by the cysteine protease SpeB leads to increased disease severity in a murine model.
575 *PLoS One*. 2011;6: e18984.
- 576
- 577

Figure Legends

Figure 1: The effect of TLCA on colony biofilm formation in *P. aeruginosa* PA14.

After five days of growth, colonies that were exposed to TLCA showed a similar hyper-wrinkled biofilm structure to that of the untreated Δphz mutant.

Figure 2: MALDI-TOF IMS analysis of *P. aeruginosa* after exposure to TLCA.

Twelve characterized specialized metabolites produced by *P. aeruginosa* were identified and visualized. Signal intensity is displayed as a heat map and shows that exposure to TLCA altered regulation of highlighted specialized metabolites compared to control. * denotes the signal is significantly up- or down-regulated in two biological replicates within the colony and □ denotes significance in the surrounding agar ($p < 0.05$). Two asterisks (**) denote the signal was significant over all three biological replicates.

Figure 3: Virulence assay with *Galleria mellonella* (greater wax moth).

Using *G. mellonella* as an infection model revealed that regardless of biofilm dispersing agent, dispersed biofilm cells show a significant increase in virulence compared to controls ($p < 0.05$).

Figure 4: PA14 Iron starvation assay.

(A & B) shows that when biofilm dispersed *P. aeruginosa* cells are exposed to TLCA there are no changes in proliferation. When exposed to iron starvation, we observe no significant difference between biofilm and dispersed biofilm cells. Confirming TLCA dispersed cells are not more sensitive to iron starvation than biofilm cells. (C & D) We observe the same relationship with planktonic cells and planktonic cells inhibited from entering the biofilm state. However, planktonic cells do show a sensitivity to iron starvation. * denotes $p < 0.05$.

Figure 5: IMS and fold change analysis of wild type PA14, *pqsH*, and *phz* mutants.

(A) IMS analysis revealed TLCA exposure induced no change in PCA production however (B) there was an increase in pyochelin production in the Δphz mutant, resembling the trend observed in wild-type experiments. □□ denotes the observed regulation was statistically significant over three biological replicates in IMS experiments ($p < 0.05$).

Figure 6: *pqs* metabolic pathway under TLCA exposure.

(A) Represents the canonical pathway for pyochelin production with the role iron-bound PQS plays in indirectly (dashed-line) activating pyochelin production. (B) However, TLCA treatment of the WT, *pqsH*, and *phz* mutants leads to an increase in pyochelin production and subsequently virulence supporting that these genes play a role in the observed increase in pyochelin production from TLCA exposure.











